13F-HR filed by Versant Venture Management, LLC
Versant Venture Management, LLC filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-03, with 7 holding rows worth $103,136,206.
- Accession
- 0000950123-24-003797
- Filer
- CIK 1560009
- Filed
- 2024-05-03
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2024
A holdings report, 7 entries on the cover page, a total value of $103,136,206 stated on the cover page (in dollars after the unit check, H1), rows summing to $103,136,206 with VALUE read as dollars as filed, 13F file number 028-16849. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 498,558 | $33,981,713 | dollars as filed | |
| SKYE BIOSCIENCE INC | 83086J200 | COM NEW | 2,007,702 | $31,400,459 | dollars as filed | |
| REPARE THERAPEUTICS INC | 760273102 | COM | 2,646,657 | $12,465,754 | dollars as filed | |
| GRITSTONE BIO INC | 39868T105 | COM | 3,561,150 | $9,152,156 | dollars as filed | |
| Adverum Biotechnologies, Inc. | 00773U108 | Common Stock | 506,822 | $7,166,463 | dollars as filed | |
| PASSAGE BIO INC | 702712100 | COM | 4,959,769 | $6,695,688 | dollars as filed | |
| ALIGOS THERAPEUTICS INC COM NEW | 01626L105 | Stock | 2,320,381 | $2,273,973 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-24-003797 | this filing | 2024-05-03 | acceptance time not in the bulk data set |